Frequency of the basal-like phenotype in African breast cancer

APMIS

Volumn 115, Issue 12, 2007, Pages 1391-1399

  Nalwoga, Hawa ^a,b   Arnes, Jarle B ^b   Wabinga, Henry ^a   Akslen, Lars A ^b  

^a MAKERERE UNIVERSITY   (Uganda)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Basal like phenotype; Breast carcinoma; Uganda

Indexed keywords

ANTIBODY; CADHERIN; CYTOKERATIN 5; CYTOKERATIN 6; ESTROGEN RECEPTOR; KI 67 ANTIGEN; P CADHERIN; PARAFFIN; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AFRICA; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER PATIENT; CANCER REGISTRY; CELL PROLIFERATION; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MITOSIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; UGANDA;

BREAST NEOPLASMS; CADHERINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-5; KERATIN-6; NEOPLASMS, BASAL CELL; PHENOTYPE; PREVALENCE; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGISTRIES; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; UGANDA;

EID: 37549067370     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2007.00862.x     Document Type: Article

References (56)

1. Ellis IO, Schnitt SJ, Sastre-Garau X, Bussolati G, Tavassoli FA, Eusebi V, et al. Invasive breast carcinoma. In: Tavassoli FA, Devilee P, editor. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon : IARC Press, 2003 13 59.
2. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999 83 : 18 29.
3. Walker RA, Gullick WJ, Varley JM. An evaluation of immunoreactivity for c-erbB-2-protein as a marker of poor short-term prognosis in breast cancer. Br J Cancer 1989 60 : 426 9.
4. Adebamowo CA, Adekunle OO. Case-controlled study of the epidemiological risk factors for breast cancer in Nigeria. Br J Surg 1999 86 : 665 8.
5. The Uganda Breast Cancer Working Group. Breast cancer guidelines for Uganda. Afr Health Sci 2003 3 : 47 50.
6. Amir H, Kaaya EE, Kwesigabo G, Kiitinya JN. Breast cancer before and during the AIDS epidemic in women and men: a study of Tanzanian Cancer Registry Data 1968 to 1996. J Natl Med Assoc 2000 92 : 301 5.
7. Sitas F, Pacella-Norman R, Carrara H, Patel M, Ruff P, Sur R, et al. The spectrum of HIV-1 related cancers in South Africa. Int J Cancer 2000 88 : 489 92.
8. Wabinga HR, Parkin DM, Wabwire-Mangen F, Nambooze S. Trends in cancer incidence in Kyadondo County, Uganda, 1960-1997. Br J Cancer 2000 82 : 1585 92.
9. Palma M, Ristori E, Ricevuto E, Giannini G, Gulino A. BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers. Crit Rev Oncol Hematol 2006 57 : 1 23.
10. Ribeiro-Silva A, Ribeiro do Vale F, Zucoloto S. Vascular endothelial growth factor expression in the basal subtype of breast carcinoma. Am J Clin Pathol 2006 125 : 512 8.
11. Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Begin LR, et al. The prognostic implication of the basal-like (cyclin E high/p27low/p53+/glomeruloid-microvascular-prolifera-tion+) phenotype of BRCA1-related breast cancer. Cancer Res 2004 64 : 830 5.
12. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004 203 : 661 71.
13. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 2005 447 : 688 94.
14. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002 161 : 1991 6.
15. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004 10 : 5367 74.
16. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000 406 : 747 52.
17. Ribeiro-Silva A, Ramalho LN, Garcia SB, Brandao DF, Chahud F, Zucoloto S. p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology 2005 47 : 458 66.
18. Rodriguez-Pinilla SM, Sarrio D, Honrado E, Hardisson D, Calero F, Benitez J, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 2006 12 : 1533 9.
19. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001 98 : 10869 74.
20. Kovacs A, Dhillon J, Walker RA. Expression of P-cadherin, but not E-cadherin or N-cadherin, relates to pathological and functional differentiation of breast carcinomas. Mol Pathol 2003 56 : 318 22.
21. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A, et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 2003 9 : 3606 14.
22. Rasbridge SA, Gillett CE, Sampson SA, Walsh FS, Millis RR. Epithelial (E-) and placental (P-) cadherin cell adhesion molecule expression in breast carcinoma. J Pathol 1993 169 : 245 50.
23. Ribeiro-Silva A, Zambelli Ramalho LN, Britto Garcia S, Zucoloto S. The relationship between p63 and p53 expression in normal and neoplastic breast tissue. Arch Pathol Lab Med 2003 127 : 336 40.
24. Ribeiro-Silva A, Zamzelli Ramalho LN, Garcia SB, Zucoloto S. Is p63 reliable in detecting microinvasion in ductal carcinoma in situ of the breast? Pathol Oncol Res 2003 9 : 20 3.
25. Nalwoga H, Odida M, Wabinga H. c-erbB-2 oncoprotein over-expression in breast cancer and its relationship to histology type and grade in a Uganda population. East Afr Med J 2006 83 : 411 5.
26. Wabinga HR. Kyadondo County. In: Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, editors. Cancer Incidence in Five Continents. Lyon : IARC press, 1997 1585 92.
27. Law : G. Counties of Uganda. January 22 2004 [cited 2006 November 03]; Available from: http: //www.statoids.com/yug.html.
28. World Health Organization : International histological classification of tumours, No. 2. Histological typing of breast tumours, 2nd ed. Geneva : WHO, 1981.
29. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957 11 : 359 77.
30. Elston CW, Ellis IO. Pathological prognostic factors in breast-cancer. 1. The value of histological grade in breast-cancer - experience from a large study with long-term follow-up. Histopathology 1991 19 : 403 10.
31. TM for the DakoCytomation Autostainer. 2006 [cited 2006 October 12]; Available from: http: //www.dako.co.uk/prod_downloadpackageinsert.pdf?objectid=111781001.
32. Arnes JB, Brunet JS, Stefansson I, Begin LR, Wong N, Chappuis PO, et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res 2005 11 : 4003 11.
33. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003 95 : 1482 5.
34. Stefansson IM, Salvesen HB, Akslen LA. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol 2004 22 : 1242 52.
35. Collett K, Stefansson IM, Eide J, Braaten A, Wang H, Eide GE, et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 2005 14 : 1108 12.
36. Ikpatt OF, Xu J, Kramtsov A, Ndoma-Egba R, Perou C, Olufunmilayo O. Hormone receptor negative and basal-like subtypes are overrepresented in invasive breast carcinoma from women of African ancestry. AACR Annual Meeting 2005 Orange County, California : Proc Am Assoc Cancer Res, 2005 46 Abstract 2550
37. Fregene A, Newman LA. Breast cancer in sub-Saharan Africa: how does it relate to breast cancer in African-American women?. Cancer 2005 103 : 1540 50.
38. Porter PL, Lund MJ, Lin MG, Yuan X, Liff JM, Flagg EW, et al. Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer 2004 100 : 2533 42.
39. Ikpatt OF, Ndoma-Egba R. Oestrogen and progesterone receptors in Nigerian breast cancer: relationship to tumour histopathology and survival of patients. Cent Afr J Med 2003 49 : 122 6.
40. Mbonde MP, Amir H, Akslen LA, Kitinya JN. Expression of oestrogen and progesterone receptors, Ki-67, p53 and BCL-2 proteins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African population. East Afr Med J 2001 78 : 360 5.
41. Ikpatt F, Kuopio T, Erekul A, Collan Y. Apoptosis in breast cancer: Nigerian vs. Finnish material. Anal Quant Cytol Histol 2002 24 : 73 80.
42. Ikpatt OF, Kuopio T, Collan Y. Proliferation in African breast cancer: biology and prognostication in Nigerian breast cancer material. Mod Pathol 2002 15 : 783 9.
43. Ikpatt OF, Kuopio T, Ndoma-Egba R, Collan Y. Breast cancer in Nigeria and Finland: epidemiological, clinical and histological comparison. Anticancer Res 2002 22 : 3005 12.
44. Tsuda H, Takarabe T, Hasegawa F, Fukutomi T, Hirohashi S. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 2000 24 : 197 202.
45. Tsuda H, Takarabe T, Hasegawa T, Murata T, Hirohashi S. Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones. Hum Pathol 1999 30 : 1134 9.
46. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006 295 : 2492 502.
47. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003 100 : 8418 23.
48. Gao Q, Adebamowo CA, Fackenthal J, Das S, Sveen L, Falusi AG, et al. Protein truncating BRCA1 and BRCA2 mutations in African women with pre-menopausal breast cancer. Hum Genet 2000 107 : 192 4.
49. Gao Q, Tomlinson G, Das S, Cummings S, Sveen L, Fackenthal J, et al. Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Hum Genet 2000 107 : 186 91.
50. Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 1998 279 : 915 21.
51. Mefford HC, Baumbach L, Panguluri RC, Whitfield-Broome C, Szabo C, Smith S, et al. Evidence for a BRCA1 founder mutation in families of West African ancestry. Am J Hum Genet 1999 65 : 575 8.
52. Panguluri RC, Brody LC, Modali R, Utley K, Adams-Campbell L, Day AA, et al. BRCA1 mutations in African Americans. Hum Genet 1999 105 : 28 31.
53. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003 100 : 10393 8.
54. Gusterson BA, Ross DT, Heath VJ, Stein T. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res 2005 7 : 143 8.
55. Korsching E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R, Isola J, et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002 82 : 1525 33.
56. Otu AA, Ekanem IO, Khalil MI, Ekpo MD, Attah EB. Characterization of breast cancer subgroups in an African population. Br J Surg 1989 76 : 182 4.